key: cord-0888566-3q0gynbu
authors: Barrett, Tessa J.; Bilaloglu, Seda; Cornwell, Macintosh; Burgess, Hannah M.; Virginio, Vitor W.; Drenkova, Kamelia; Ibrahim, Homam; Yuriditsky, Eugene; Aphinyanaphongs, Yin; Lifshitz, Mark; Xia Liang, Feng; Alejo, Julie; Smith, Grace; Pittaluga, Stefania; Rapkiewicz, Amy V.; Wang, Jun; Iancu‐Rubin, Camelia; Mohr, Ian; Ruggles, Kelly; Stapleford, Kenneth A.; Hochman, Judith; Berger, Jeffrey S.
title: Platelets contribute to disease severity in COVID‐19
date: 2021-09-29
journal: J Thromb Haemost
DOI: 10.1111/jth.15534
sha: ca2e162c96ed57b9a80b13d6f5a6e8ef6a36c4f4
doc_id: 888566
cord_uid: 3q0gynbu

OBJECTIVE: Heightened inflammation, dysregulated immunity, and thrombotic events are characteristic of hospitalized COVID‐19 patients. Given that platelets are key regulators of thrombosis, inflammation, and immunity they represent prime candidates as mediators of COVID‐19‐associated pathogenesis. The objective of this study was to understand the contribution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to the platelet phenotype via phenotypic (activation, aggregation) and transcriptomic characterization. APPROACH AND RESULTS: In a cohort of 3915 hospitalized COVID‐19 patients, we analyzed blood platelet indices collected at hospital admission. Following adjustment for demographics, clinical risk factors, medication, and biomarkers of inflammation and thrombosis, we find platelet count, size, and immaturity are associated with increased critical illness and all‐cause mortality. Bone marrow, lung tissue, and blood from COVID‐19 patients revealed the presence of SARS‐CoV‐2 virions in megakaryocytes and platelets. Characterization of COVID‐19 platelets found them to be hyperreactive (increased aggregation, and expression of P‐selectin and CD40) and to have a distinct transcriptomic profile characteristic of prothrombotic large and immature platelets. In vitro mechanistic studies highlight that the interaction of SARS‐CoV‐2 with megakaryocytes alters the platelet transcriptome, and its effects are distinct from the coronavirus responsible for the common cold (CoV‐OC43). CONCLUSIONS: Platelet count, size, and maturity associate with increased critical illness and all‐cause mortality among hospitalized COVID‐19 patients. Profiling tissues and blood from COVID‐19 patients revealed that SARS‐CoV‐2 virions enter megakaryocytes and platelets and associate with alterations to the platelet transcriptome and activation profile.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID- 19) global pandemic. COVID-19 is a complex disease with a broad spectrum of clinical presentations, ranging from asymptomatic to severe respiratory failure with multi-organ failure and death.

Microvascular thrombosis of the pulmonary vasculature and other vascular beds is frequently observed in COVID-19. 1,2 Patients infected with SARS-CoV-2 are at heightened risk for both venous and arterial thrombosis, which further contribute to organ failure and all-cause mortality. 3, 4 Autopsy and clinical data from our group and others highlight the role of megakaryocytes and platelets in the pathogenesis of COVID-19. 1, 5, 6 Thrombocytopenia is a common laboratory abnormality in critically ill patients 7 and is associated with poor clinical outcomes, including death. 7, 8 Thrombocytopenia has been reported in patients hospitalized with COVID-19, and lower platelet counts are associated with worse clinical outcomes. 9 A meta-analysis of 31 studies with 7613 participants noted a lower platelet count in severe COVID-19 infection and was associated with a 3-fold increase in the risk of developing severe COVID-19. 10 However, there is uncertainty on the different cut-offs of platelet count in COVID-19 and the platelet count trajectory during hospitalization.

Other indices of platelets, including platelet size and platelet maturity, are associated with increased platelet activity and clinical events. [11] [12] [13] Larger platelets are more metabolically active and have a greater prothrombotic potential, 14 with increased mean platelet volume (MPV) associated with increased morbidity and all-cause mortality. 15 Immature platelet fraction (IPF) reflects the number of circulating young platelets, and increased IPF is associated with morbidity and mortality in multiple disease states. [16] [17] [18] Platelets are shed into circulation by megakaryocytes, and during this process, megakaryocytes distribute their transcriptome into platelets. Once in the circulation, platelets can respond to local and systemic conditions and affect other cell types, including monocytes and endothelial cells. [19] [20] [21] Platelet activity is associated with the platelet ribonucleic acid (RNA) expression profiles, and platelet-viral interactions alter the platelet transcriptome. 22 Consistent with increased platelet activity (increased P-selectin and PAC-1 (activated GP IIb/ IIIa) expression), one study reports that platelets isolated from COVID-19 patients are hyperreactive and have an altered transcriptomic signature compared to disease-free controls. 6 Several genome-wide association studies (GWAS) have identified genetic regulators of platelet count and platelet size. 23 In addition, recent studies have found that platelet immaturity has a distinct platelet transcriptome. 24, 25 Thus, transcriptomic profiling of platelets isolated from patients infected with SARS-CoV-2 may provide insight into platelet count, size, and maturity during COVID-19.

In this study, we analyzed platelet indices from the complete blood count (CBC) data from NYU Langone Health (NYULH), a multihospital health system in New York City, to investigate platelet indices at presentation and trajectory during hospitalization. Following adjustment for demographics, clinical risk factors, medication use, and biomarkers of inflammation and thrombosis, platelet count, size, and immaturity are all associated with increased critical illness and all-cause mortality. Additionally, we demonstrate SARS-CoV-2 present in platelets of hospitalized COVID-19 patients and provide evidence that COVID-19 platelets are reprogrammed toward a prothrombotic phenotype. In vitro studies with megakaryocytes highlight that the transcriptomic Support Grant NIH/NCI P30CA016087. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.

In vitro mechanistic studies highlight that the interaction of SARS-CoV-2 with megakaryocytes alters the platelet transcriptome, and its effects are distinct from the coronavirus responsible for the common cold (CoV-OC43).

Conclusions: Platelet count, size, and maturity associate with increased critical illness and all-cause mortality among hospitalized COVID-19 patients. Profiling tissues and blood from COVID-19 patients revealed that SARS-CoV-2 virions enter megakaryocytes and platelets and associate with alterations to the platelet transcriptome and activation profile.

COVID-19, megakaryocytes, platelets, thrombosis ESSENTIALS • Thrombosis, inflammation, and dysregulated immunity are characteristic of hospitalized COVID-19 patients.

• COVID-19 hospital admission platelet count, size, and maturity associate with critical illness and mortality.

• COVID-19 platelets are hyperreactive and have a unique transcriptomic profile.

• Anti-platelet therapy use in hospitalized COVID-19 patients may reduce adverse clinical outcomes.

reprogramming mediated by SARS-CoV-2 is distinct from the coronavirus responsible for the common cold (CoV-OC43). Our findings support investigating the use of anti-platelet therapy in COVID-19 patients.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Data were obtained from the electronic health record (Epic Systems), which is an integrated electronic health record (EHR), including all inpatient and outpatient visits in the health system. At all four NYULH inpatient facilities, routine CBC for individuals with suspected or confirmed diagnoses of COVID-19 was included in COVID-19--specific admission order sets in the EHR at the time of hospital admission. At all NYULH sites, CBC assay was measured using Sysmex R XN-Series of automated hematology analyzers (TOA Medical Electronics). The initial platelet indices and all platelet indices measured during hospital admission were recorded for all eligible patients. The measures analyzed were platelet count, mean platelet volume (MPV), and IPF (%).

The platelet count was stratified into low (thrombocytopenia; <149 × 10 9 /L), normal (150-400 × 10 9 /L), and high (>401 × 10 9 /L). We conducted sensitivity analyses using different severities of thrombocytopenia (<49 × 10 9 /L, 50-100 × 10 9 /L, and 101-150 × 10 9 /L). Both MPV and IPF were stratified into tertiles based on values obtained at baseline.

Demographic variables included age, sex, race/ethnicity (defined as non-Hispanic White, non-Hispanic Black, Hispanic, Asian, multiracial/other, and unknown), smoking status, and body mass index (BMI). Pre-existing comorbidities included hypertension, hyperlipidemia, coronary artery disease (CAD), heart failure, diabetes, chronic kidney disease, and atrial fibrillation.

Prior medication information included statins, beta-blockers, angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB), and oral anticoagulants. Critical illness was defined as mechanical ventilation or transfer to the intensive care unit.

Continuous variables are shown using mean (standard deviation Logistic regression models were generated to estimate the odds of the study endpoints, adjusted for demographics, clinical comorbidities, vital signs at presentation, and baseline medications.

Covariates in the multivariable models included age; sex; race; BMI; tobacco use; race-ethnicity; hypertension; hyperlipidemia; chronic kidney disease; prior heart failure; asthma or chronic obstructive pulmonary disease; CAD; cancer; diabetes; temperature; SpO 2 ;

and initial laboratory results for lymphocyte count, ferritin and C-reactive protein (CRP), D-dimer, creatinine, troponin, and procalcitonin. Statistical analyses were performed using statistical software R (R Foundation for Statistical Computing), with packages ggplot2, and base R. Statistical tests are two-sided, and P-values <.05 were considered statistically significant. For COVID-19 patients, enrollment criteria included age greater than 18, hospital admission, positive SARS-CoV-2 testing, and informed consent. COVID-19 patients were monitored until discharge or death.

After an initial 2 cc discard, blood was collected into tubes containing 3.2% sodium citrate. Blood was allowed to rest for 10 min prior to isolation of platelet rich plasma by centrifugation at 200 g for 10 min.

Platelets were isolated and purified by incubation with microbeads to deplete leukocytes and red blood cells (EasySep™ Human CD45 Depletion Kit II and EasySep™ RBC Depletion Reagent). Isolated platelets lysed in 500 uL of trizol and stored at −80°C. RNA was isolated with Direct-zol RNA microspin columns (Zymo Research), and quality and quantity were determined with a Bioanalyzer 2100 (Agilent Technologies). Sequencing libraries were barcoded and prepared using the Clontech SMART-Seq HT with Nxt HT kit (Takara Bio USA), and libraries sequenced single end on a Illumina NovaSeq 6000.

Refer to Appendix S1 in supporting information. Data are accessible via GSE176480.

Refer to Appendix S1. 2.5.6 | Megakaryocyte and platelet immunohistochemistry, transmission electron microscopy, and in situ hybridization Refer to Appendix S1.

After an initial 2 cc discard, blood was collected into tubes containing 3.2% sodium citrate. Blood was allowed to rest for 10 min prior to isolation of platelet rich plasma by centrifugation at 200 g for 10 min.

Aggregation was measured using a light transmission aggregometry (Helena AggRAM) in response to ADP (1 µM), epinephrine (0.1 µM), and collagen (0.2 µM) at 37°C under stirred conditions as previously described. 26 3 | RE SULTS

Biomarkers of platelet activation associate with critical illness and death in patients with COVID-19, 5 and viruses are known to directly influence platelet count and size. 27, 28 To investigate the consequence of SARS-CoV-2 infection on platelet count, size, and maturity, and the outcomes of critical illness and death, we analyzed CBCs collected from 3915 patients hospitalized with COVID-19 within the NYULH system between March 2, 2020 and June 25, 2020. The median age was 65 years (IQR, 53-77), 42.9% were female, and 36.8%

were White. A total of 1678 (38.5%) had diabetes, 580 (13.3%) had cancer, and 994 (22.8%) had CAD (Table 1) . Overall, 1415 (36%) experienced critical illness, and 948 (29%) were discharged to hospice or died at a median of 10 (IQR, 5-22) days after hospital admission.

Among 3915 patients with platelet count data at hospital presentation, 2894 (73%) had a normal platelet count (150-400 × 10 9 /L), 795 (20%) had thrombocytopenia (<150 × 10 9 /L), and 226 (7%) had an elevated platelet count (>400 × 10 9 /L). Patients with lower platelet counts were older; more likely to be male; and more likely to have comorbidities, including chronic kidney disease, CAD, and heart failure (Table S1 in supporting information). Critical illness and all-cause mortality were increased in patients with thrombocytopenia ( Figure 1A ). Compared to those with a normal platelet count, patients with thrombocytopenia were more likely to experience critical illness (adjusted odds ratio [adjOR] 1.4, 95% confidence interval [CI]

1.1-1.7, P = .0002) and all-cause mortality (adjOR 1.6, 95% CI 1.3-1.9, P = .0002, Figure 1A ). When thrombocytopenia was further stratified into severe <50 × 10 9 /L, moderate 50-100 × 10 9 /L, and mild 100-150 × 10 9 /L, the association between platelet count and adverse events was most pronounced in subjects with a platelet count <50 × 10 9 /L (Table S2 in supporting information). Interestingly, there was a trend toward less critical illness in those with elevated platelet counts >400 × 10 9 /L, but this did not reach statistical significance compared to a normal platelet count (adjOR 0.75, 95% CI 0.53-1.05, P = .10). Platelet count trajectory by critical illness and all-cause mortality is presented in Figure 2A and Figure S1 in supporting information. Platelet count increased during the course of hospitalization and peaked at approximately 8 days into hospitalization.

Median MPV was 10.5 fL (IQR, 9.9-11.2). When stratified into tertiles, patients with a higher MPV were older; more frequently African American; and more likely to have CAD, diabetes, and heart failure (Table S3 in supporting information). Critical illness and all-cause mortality were highest in patients with a higher MPV ( Figure 1B ). After adjustment for demographics, comorbidities, prior medications, and baseline laboratory values, patients in the highest MPV tertile had higher odds of critical illness (adjOR 1.5, 95% CI 1.3-1.8) and all-cause mortality (adjOR 1.3, 95% CI 1.1-1.5) compared to lowest MPV tertile ( Figure 1B) . Because MPV inversely correlates with platelet count, we excluded subjects with a low platelet count in a sensitivity analysis and found that subjects in the highest MPV tertile had higher odds of critical illness and all-cause mortality ( Figure S2A -B in supporting information). The trajectory of MPV during hospitalization stratified by critical illness and all-cause mortality is presented in Figure 2B . In contrast to patients without an event, MPV increases in patients who were critical ill or died.

Immature platelet fraction (IPF) was collected beginning on April 23, 2020, and was available for 427 patients. Median IPF was 7.4% (IQR, 4.9-10.5). Stratified into tertiles, there were no significant differences between the three tertiles in age or comorbidities (Table S4 in supporting information). Critical illness was more common in patients with the highest IPF tertile; however, mortality was not significantly different between groups ( Figure 1C ). After adjustment for demographics, comorbidities, prior medications, and baseline laboratory values, patients belonging to the highest tertile of IPF had higher odds of critical illness (adjOR 2.4, 95% CI 1.4-4.2) and a trend toward death (adjOR 2.1, 95% CI 0.9-5.0) versus the lowest tertile ( Figure 1C ). After excluding individuals with a low platelet count in a sensitivity analysis, subjects in the highest IPF tertile had higher odds of critical illness ( Figure S2A-B) . The trajectory of IPF during hospitalization stratified by critical illness and all-cause mortality is presented in Figure 2 and Figure S1.

In the setting of viral infections, platelets can internalize viral particles, including influenza, human immunodeficiency virus (HIV), hepatitis C virus, and dengue, resulting in platelet activation. 27, 29 To explore the interaction between SARS-CoV-2 and platelets, we first assessed whether megakaryocytes, the precursor of platelets, can internalize SARS-CoV-2. Autopsy data from COVID-19 patients revealed megakaryocytes in the bone marrow, with morphology consistent with active platelet production ( Figure 3A) . Furthermore, in one autopsy in which the bone marrow was examined within 10 days of COVID-19 symptom onset, megakaryocytes with SARS-CoV-2 engulfed virions were found ( Figure 3B ). Additionally, by in situ hybridization, we find evidence of replicating SARS-CoV-2 within a lung megakaryocyte from a deceased COVID-19 patient ( Figure S3 in supporting information).

Consistent with the observation in megakaryocytes and a previous report in platelets, 30 we find viral particles present in approximately 39% of circulating platelets from three COVID-19positive patients, indicative that SARS-CoV-2 is either transferred from megakaryocytes to platelets or actively engulfed by circulating platelets ( Figure 3C , Table S5 in supporting information). The presence of SARS-CoV-2 in platelets did not appear to alter their morphology (Table S6 in supporting information). In further support

Overall population (n = 3915) F I G U R E 1 Critical illness and all-cause mortality stratified by platelet count, mean platelet volume (MPV; fL), and immature platelet fraction (IPF; %). A, Stratification based on low, normal, and elevated platelet count at hospital presentation and adjusted odds ratio for critical illness and all-cause mortality based on platelet count. B, Stratification based on tertile of MPV at hospital presentation and adjusted odds ratio for critical illness and all-cause mortality based on MPV. C, Stratification based on tertile of IPF at hospital presentation and adjusted odds ratio for critical illness and all-cause mortality based on IPF. Covariates in the multivariable models included age, sex, race, body mass index, tobacco use, race-ethnicity, hypertension, hyperlipidemia, chronic kidney disease, prior heart failure, asthma or chronic obstructive pulmonary disease, coronary artery disease, cancer, diabetes, temperature, SpO 2 , and initial laboratory results for lymphocyte count, ferritin and C-reactive protein, D-dimer, creatinine, troponin, and procalcitonin and ASGR1. 32 At the level of the platelet transcriptome, only CD147 was found to be expressed ( Figure 3F ), and consistent with this, only CD147 was found to be expressed on the surface of primary megakaryocytes ( Figure 3G , Figure S4 in supporting information).

Because platelets are affected by viral entry, 33 we recruited a cohort of eight hospitalized COVID-19 patients and ten age, sex, and race/ ethnicity controls with similar risk factor profiles (demographics in Table S7 in supporting information). While platelet count was similar between the groups, MPV was increased in subjects with COVID-19

( Figure 4A-B) . Platelet aggregation in response to submaximal platelet agonists (ADP, 1 uM; epinephrine, 0.1 uM; and collagen, 0.2 uM) revealed that platelets from COVID-19 patients were hyperreactive compared to controls ( Figure 4C-D) . However, in our cohort, we found a degree of heterogeneity associated with platelet count and activity within the COVID-19 population.

To investigate the potential mechanism(s) as to how SARS-CoV-2 may alter the platelet phenotype, we performed RNA sequencing of RNA isolated from highly purified platelets 26 and S100A9, relative to vehicle-treated cells ( Figure 5D , red bars).

Conversely, exposure to CoV-OC43 did not result in changes to

LGALS3BP and S100A9 mRNA transcription ( Figure 5D , blue bars),

indicating that direct SARS-CoV-2-megakaryocyte interactions can induce our observed COVID-19 platelet signature transcriptome.

Notably, CD147 antibody-mediated blocking significantly reduced the expression of SARS-CoV-2, S100A9, and S100A8 on megakaryocytes following incubation with SARS-CoV-2 ( Figure Figure 5F ). To understand the relationship between the transcriptional changes and the increased platelet activity seen in patients with COVID-19, we correlated each subject's eigengene score with their platelet aggregation to ADP, epinephrine, and collagen. The resulting correlations demonstrate that differential expression of these specific metabolic pathways is directly associated with an increased platelet response to stimulus ( Figure 5G ).

Because platelet count, size, and maturity were associated with adverse outcomes; we used our transcriptomic data to shed light (FEN1) was suppressed relative to platelets from control subjects.

Among the 30 genes previously identified to regulate MPV, 15

were differentially expressed (padj <.1) in COVID-19 versus controls ( Figure 6B ). Coagulation factor II thrombin receptor (F2R), We found genes differentially regulated in COVID-19 versus controls that regulate platelet count and size to be the same comparing COVID-19 patients who later died to controls ( Figure 6A-B) . Immature platelet fraction is an excellent proxy for reticulated (younger) platelets. Immature platelets are larger, contain a higher amount of RNA, and can produce various proteins typical for platelet activation (e.g., GPIIb/IIIa, P-selectin). 36 Reticulated or newly formed platelets have a distinct prothrombotic transcriptomic profile. 25 To understand if platelets isolated from patients with COVID-19 had a transcriptomic profile characteristic of immature prothrombotic platelets, we compared our RNAseq results to a publically available dataset comparing immature (reticulated) versus mature platelets. 25 We found a significant overlap between transcripts differentially expressed between reticulated versus mature platelets and platelets from COVID-19 versus controls ( Figure 6D , R = 0.38, P = 3.7 × 10 −10 , Table S8 in supporting information). Overall, 211/256 transcripts were differentially expressed in the same direction, of which 167 were increased and 44 decreased. Not surprisingly, we find a stronger association between the transcriptome of COVID-19 patients who died versus controls and between reticulated versus mature platelets ( Figure 6E , R = 0.44, P = 1.9 × 10 −12 , Table S9 in supporting information), suggesting that COVID-19 patients who died have a more prothrombotic platelet profile.

Platelets are increasingly recognized as key mediators of inflammation and immune dysfunction. 21, 37 Patients with COVID-19 are at heightened risk of critical illness and all-cause mortality secondary to a heightened inflammatory state and altered immune phenotype. [38] [39] [40] Thus, it is not surprising that platelets contribute to the pathophysiology of COVID-19 and play a significant role in the development of COVID-19--associated complications. We report that SARS-CoV-2 infects bone marrow megakaryocytes and show for the first time that virions are present in circulating platelets.

Additionally, we provide evidence that SARS-CoV-2 induces transcriptomic changes to megakaryocytes, which are unique relative to

CoV-OC43, a coronavirus responsible for the common cold. 31 In a large cohort of hospitalized COVID-19 patients, we find that markers of platelet activity (platelet size and platelet maturity) are significantly associated with both critical illness and all-cause mortality, even after adjusting for demographics, comorbidities, medication, and clinical laboratory values, including biomarkers of inflammation and thrombosis (e.g., D-dimer, CRP).

Consistent with previous data, we found increased platelet ac- Collectively, our findings highlight the importance of platelet indices at initial hospital presentation to aid as a surrogate biomarker for F I G U R E 5 Platelets from COVID-19 patients have a unique transcriptome. A) Principal component analysis from top varied genes, (B) heat map of significantly differentially expressed platelet transcripts (adjusted P-value <.05, |log2fc| >1) from COVID-19 patients and control donors. Red indicates increased relative expression, and blue indicates decreased relative expression, and (C) volcano plot (red dots: adjusted P-value <.05, dark red: log2fc >1; blue dots: adjusted P-value <.05, dark blue < −1) (D) LGALS3BP, and S100A9 mRNA expression in Meg-01 cells treated with either media control, SARS-CoV-2, or CoV-OC43 for 24 h. SARS-CoV-2 incubations performed at 37°C, CoV-OC43 incubations performed at 33°C. E, Gene set enrichment analysis of Hallmark pathways, displayed pathways represent those with an adjusted P < .05. F, Weighted correlation network analysis ( However, whether a more aggressive antithrombotic strategy with platelet-directed therapies in these patients would alter the critical illness course is unknown and under investigation.

F I G U R E 6 Platelet transcriptomics and comparative analyses with established gene signatures. A, -log10(adj pvalue) for genes associated with platelet count with red indicating genes positively differentially expressed between COVID-19 and control, and blue indicating genes negatively differentially expressed between COVID-19 and control. Heatmap above shows raw scaled gene counts across all samples and genes. B, -log10(adj pvalue) for genes associated with mean platelet volume with red indicating genes positively differentially expressed between COVID-19 patients and control, and blue indicating genes negatively differentially expressed between COVID-19 patients and control. Heatmap above shows raw scaled gene counts across all samples and genes. C, GCKR, BAZ2A, and ITPK1 mRNA expression in Meg-01 cells treated with either media control, SARS-CoV-2, or CoV-OC43 for 24 h. SARS-CoV-2 incubations performed at 37°C, CoV-OC43 incubations performed at 33°C. D-E, Scatterplots of fold change differences comparing reticulated platelets (RP) versus mature platelets (MP), and COVID-19 patients versus control. Size and color of dots indicative of the respective P-value of the fold change; all genes shown have adjusted P-value <.05 for both RP versus MP comparison and COVID-19 patients versus controls. Squares indicate number of genes in each quadrant. Correlation of fold changes shown on plot F I G U R E 7 Summary of platelet activation by SARS-CoV-2

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

Biomarkers of platelet activity and vascular health associate with thrombosis and mortality in patients with COVID-19

Platelet gene expression and function in COVID-19 patients

Thrombocytopenia and prognosis in intensive care

Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements

Thrombocytopenia and its association with mortality in patients with COVID-19

The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants

Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia

A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia

Immature platelet fraction: establishment of a reference interval and diagnostic measure for thrombocytopenia

Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy

Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis

Association of immature platelets with adverse cardiovascular outcomes

Immature platelet fraction predicts coagulopathy-related platelet consumption and mortality in patients with sepsis

An elevated percentage of reticulated platelet is associated with increased mortality in septic shock patients

Activated platelets induce endothelial cell activation via an interleukin-1beta pathway in systemic lupus erythematosus

Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3

Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis

Platelets and infection -an emerging role of platelets in viral infection

New gene functions in megakaryopoiesis and platelet formation

Megakaryocyte and platelet transcriptomics for discoveries in human health and disease

Transcriptome analysis of reticulated platelets reveals a prothrombotic profile

Platelet-Derived MRP-14 induces monocyte activation in patients with symptomatic peripheral artery disease

Circulating platelets as mediators of immunity, inflammation, and thrombosis

Platelets: the unsung hero of the immune response

Platelets endocytose viral particles and are activated via TLR (Toll-Like Receptor) signaling

SARS-CoV-2 initiates programmed cell death in platelets

Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2

Platelets in immune response to virus and immunopathology of viral infections

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

WGCNA: an R package for weighted correlation network analysis

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

Platelets fuel the inflammasome activation of innate immune cells

Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

C-reactive protein and clinical outcomes in patients with COVID-19

COVID-19 patients exhibit reduced procoagulant platelet responses

Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

COVID-19: the vasculature unleashed

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Targeting potential drivers of COVID-19: neutrophil extracellular traps

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Platelet transcriptome profiling in HIV and ATP-binding cassette subfamily C member 4 (ABCC4) as a mediator of platelet activity

Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications

Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome

Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness

Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

Role of platelets in thrombosis and hemostasis

Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogenindependent platelet aggregation and fibronectin-mediated protein wave of hemostasis

Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents

The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors

Lung megakaryocytes are immune modulatory cells

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Temporal dynamics in viral shedding and transmissibility of COVID-19

Severe obesity and bariatric surgery alter the platelet mRNA profile

Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?

We thank NYU Langone Health DART Microscopy Lab, Chris Petzold, and Kristen Dancel-Manning for their assistance with TEM work, and the Genomic Technology Core for RNA sequencing.

All authors declare no conflicts of interest.

JB had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.